TY - JOUR
T1 - Rapid steroid withdrawal in hepatitis C virus-positive kidney transplant recipients
AU - Akalin, Enver
AU - Murphy, Barbara
AU - Sehgal, Vinita
AU - Ames, Scott
AU - Daly, Lisa
AU - Bromberg, Jonathan S.
N1 - Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2004/8
Y1 - 2004/8
N2 - The effects of rapid steroid withdrawal (SW) on kidney transplantation (KT) outcome were investigated in 12 HCV+ patients in a prospective cohort study. These results were compared with 17 HCV+ patients who received KT in the prior 2 yr and treated with a standard prednisone taper protocol. SW patients received only 6 d of steroid treatment after transplantation. Eleven received Thymoglobulin and one Basiliximab induction treatment along with a calcineurin inhibitor and mycophenolate mofetil. Patient and graft survival was 92% in SW group (median follow-up 12 months, range 6-17), and 92 and 82% in the historic control group respectively (median follow-up 21 months, range 11-27). In the SW and control-group, acute rejection rates were 9 and 18%, and mean creatinine levels at last follow-up 1.30 ± 0.36 and 1.68 ± 0.58 mg/dL respectively. Only two SW patients had an increase in liver function tests during follow-up (18%), compared with six patients in the control group (43%). This study demonstrates that rapid SW is safe for HCV+ KT recipients, without an increase in acute rejection episodes or liver function abnormalities in the short term.
AB - The effects of rapid steroid withdrawal (SW) on kidney transplantation (KT) outcome were investigated in 12 HCV+ patients in a prospective cohort study. These results were compared with 17 HCV+ patients who received KT in the prior 2 yr and treated with a standard prednisone taper protocol. SW patients received only 6 d of steroid treatment after transplantation. Eleven received Thymoglobulin and one Basiliximab induction treatment along with a calcineurin inhibitor and mycophenolate mofetil. Patient and graft survival was 92% in SW group (median follow-up 12 months, range 6-17), and 92 and 82% in the historic control group respectively (median follow-up 21 months, range 11-27). In the SW and control-group, acute rejection rates were 9 and 18%, and mean creatinine levels at last follow-up 1.30 ± 0.36 and 1.68 ± 0.58 mg/dL respectively. Only two SW patients had an increase in liver function tests during follow-up (18%), compared with six patients in the control group (43%). This study demonstrates that rapid SW is safe for HCV+ KT recipients, without an increase in acute rejection episodes or liver function abnormalities in the short term.
KW - Hepatitis C virus
KW - Kidney transplantation
KW - Steroid withdrawal
KW - Thymoglobulin
UR - http://www.scopus.com/inward/record.url?scp=4043090635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4043090635&partnerID=8YFLogxK
U2 - 10.1111/j.1399-0012.2004.00177.x
DO - 10.1111/j.1399-0012.2004.00177.x
M3 - Article
C2 - 15233814
AN - SCOPUS:4043090635
SN - 0902-0063
VL - 18
SP - 384
EP - 389
JO - Clinical Transplantation
JF - Clinical Transplantation
IS - 4
ER -